Latest intangible assets for EPZM: $41M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Epizyme (EPZM) currently reports a intangible assets of $41M as of June 2022. That compares with $45M in the prior-year period — down 9.2% year over year. Use the charts on this page to explore Epizyme's intangible assets history and peer comparisons.
Epizyme's intangible assets decreased from $45M to $41M — a 9.2% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Epizyme reported $41M in intangible assets as of June 2022. That compares with $45M in the prior-year period — down 9.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current intangible assets of $41M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Epizyme, and consider following EPZM for alerts when major investors trade the stock.
Epizyme is classified in the Healthcare sector. On intangible assets, it currently shows $41M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPZM with unrelated industries.